TYMP
Thymidine phosphorylase
As of the edition of 20 October 2026, TYMP (thymidine phosphorylase, UniProt P19971) has 1 drug tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P19971
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 4
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Inherited and neonatal; Skin and connective tissue; Chemically induced; Heart and blood vessels
- Registered trials of its drugs
- 97
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tipiracil | Marketed | Phase 3 | Ends 2034 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Servier | Route B |
The other 1 company at TYMP
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at TYMP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.